Home > Oncology > ASCO 2020 > HER2-expressing metastatic colorectal cancer: trastuzumab deruxtecan

HER2-expressing metastatic colorectal cancer: trastuzumab deruxtecan

In an initial report of patients with heavily pre-treated metastatic, HER2-expressing colorectal cancer, preliminary efficacy was observed with trastuzumab deruxtecan, particularly in patients with the highest degree of HER2-positivity.

Prof. Salvatore Siena (University of Milan Niguarda Cancer Center, Italy) presented results from the DESTINY-CR101 study, which stratified 3 cohorts of patients [1]. Cohort A had HER2-overexpressing patients who had scores of 3 or higher according to immunohistochemistry testing (IHC 3 plus), as well as a score above 2 by *in situ* hybridisation (ISH). Cohort B were patients whose tumours were IHC 2 and above but were ISH-negative; cohort C were patients whose tumours were IHC >1. All patients (n=90) enrolled in the trial had tumours that were *RAS/BRAF*-wildtype and expressed HER2. A single patient had an *NRAS* mutation. All had received at least two prior line...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on